# Fate Therapeutics (FATE) — Earnings

FATE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/fate/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.29 |
| EPS estimate | −$0.35 |
| EPS surprise | +17.33% |
| Revenue surprise | +120.65% |
| Revenue | $1.9M |
| Revenue estimate | $864,255.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1434316/000095017025107309/fate-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$0.35 | −$0.29 | 17.33% | $864,255.00 | $1.9M |
| Q1 2025 | May 13, 2025 | −$0.38 | −$0.32 | 16.51% | $1.1M | $1.6M |
| Q4 2024 | Mar 5, 2025 | −$0.43 | −$0.44 | -1.73% | $1.4M | $1.9M |
| Q3 2024 | Nov 12, 2024 | −$0.42 | −$0.40 | 3.96% | $1.2M | $3.1M |
| Q2 2024 | Aug 13, 2024 | −$0.46 | −$0.33 | 28.80% | $1.3M | $6.8M |
| Q1 2024 | May 9, 2024 | −$0.47 | −$0.47 | 0.38% | $1.7M | $1.9M |
| Q4 2023 | Feb 26, 2024 | −$0.52 | −$0.45 | 13.83% | $1.5M | $1.7M |
| Q3 2023 | Nov 8, 2023 | −$0.56 | −$0.46 | 17.84% | $1.6M | $1.9M |
| Q2 2023 | Aug 8, 2023 | −$0.59 | −$0.54 | 8.24% | $5.4M | $933,000.00 |
| Q1 2023 | May 3, 2023 | −$0.62 | −$0.19 | 69.50% | $34.4M | $59.0M |
| Q4 2022 | Feb 28, 2023 | −$0.86 | −$0.58 | 32.75% | $17.9M | $44.4M |
| Q3 2022 | Nov 3, 2022 | −$0.90 | −$0.86 | 3.91% | $15.3M | $15.0M |
| Q2 2022 | Aug 3, 2022 | −$0.83 | −$0.79 | 4.72% | $12.5M | $18.5M |
| Q1 2022 | May 4, 2022 | −$0.77 | −$0.68 | 11.12% | $9.0M | $18.4M |
| Q4 2021 | Feb 28, 2022 | −$0.67 | −$0.72 | -8.09% | $11.3M | $17.1M |
| Q3 2021 | Nov 4, 2021 | −$0.57 | −$0.45 | 20.98% | $8.1M | $14.2M |
| Q2 2021 | Aug 4, 2021 | −$0.52 | −$0.58 | -11.60% | $6.8M | $13.4M |
| Q1 2021 | May 5, 2021 | −$0.43 | −$0.48 | -10.45% | $6.6M | $11.1M |
| Q4 2020 | Feb 24, 2021 | −$0.39 | −$0.61 | -55.18% | $5.0M | $15.9M |
| Q3 2020 | Nov 5, 2020 | −$0.33 | −$0.68 | -106.00% | $7.3M | $7.6M |

## Frequently Asked Questions

### When did Fate Therapeutics (FATE) last report earnings?

Fate Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did FATE beat earnings estimates?

Yes. Fate Therapeutics reported EPS of −$0.29 for Q2 2025 against a −$0.35 estimate — a 17.33% beat.

### How much revenue did FATE report last quarter?

Fate Therapeutics reported $1.9M in revenue for Q2 2025, against a consensus estimate of $864,255.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).